Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

haemonetics corp. - HAE

HAE

Close Chg Chg %
80.01 0.29 0.36%

Closed Market

80.30

+0.29 (0.36%)

Volume: 263.87K

Last Updated:

Dec 26, 2025, 3:59 PM EDT

Trade Now

Company Overview: haemonetics corp. - HAE

HAE Key Data

Open

$79.46

 Day Range

79.41 - 80.44

52 Week Range

47.32 - 87.30

 Market Cap

$3.75B

Shares Outstanding

46.81M

 Public Float

46.05M

Beta

0.30

 Rev. Per Employee

N/A

P/E Ratio

23.34

 EPS

$3.44

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

758.84K

  

HAE Performance

1 Week
 
 0.09%
 
1 Month
 
 -1.32%
 
3 Months
 
 66.66%
 
1 Year
 
 3.49%
 
5 Years
 
 -32.40%
 

HAE Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 11
Full Ratings ➔

About haemonetics corp. - HAE

Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, and Hospital. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.

HAE At a Glance

Haemonetics Corp.
125 Summer Street
Boston, Massachusetts 02110
Phone 1-781-848-7100 Revenue 1.36B
Industry Medical Specialties Net Income 167.68M
Sector Health Technology 2025 Sales Growth 3.955%
Fiscal Year-end 03 / 2026 Employees 3,023
View SEC Filings

HAE Valuation

P/E Current 23.342
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 19.118
Price to Sales Ratio 2.356
Price to Book Ratio 3.712
Price to Cash Flow Ratio 17.64
Enterprise Value to EBITDA 12.376
Enterprise Value to Sales 3.073
Total Debt to Enterprise Value 0.307

HAE Efficiency

Revenue/Employee 450,156.798
Income Per Employee 55,467.747
Receivables Turnover 6.715
Total Asset Turnover 0.586

HAE Liquidity

Current Ratio 1.617
Quick Ratio 0.986
Cash Ratio 0.531

HAE Profitability

Gross Margin 52.566
Operating Margin 16.339
Pretax Margin 15.584
Net Margin 12.322
Return on Assets 7.217
Return on Equity 18.832
Return on Total Capital 7.969
Return on Invested Capital 9.295

HAE Capital Structure

Total Debt to Total Equity 156.347
Total Debt to Total Capital 60.99
Total Debt to Total Assets 52.361
Long-Term Debt to Equity 118.377
Long-Term Debt to Total Capital 46.179
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Haemonetics Corp. - HAE

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
993.20M 1.17B 1.31B 1.36B
Sales Growth
+14.10% +17.67% +12.01% +3.95%
Cost of Goods Sold (COGS) incl D&A
515.04M 578.43M 632.52M 645.50M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
97.75M 93.31M 97.22M 115.59M
Depreciation
41.15M 51.21M 55.81M 59.99M
Amortization of Intangibles
56.60M 42.10M 41.40M 55.60M
COGS Growth
+8.46% +12.31% +9.35% +2.05%
Gross Income
478.16M 590.23M 676.54M 715.33M
Gross Income Growth
+20.86% +23.44% +14.62% +5.73%
Gross Profit Margin
+48.14% +50.51% +51.68% +52.57%
2022 2023 2024 2025 5-year trend
SG&A Expense
366.91M 423.03M 468.40M 492.99M
Research & Development
45.98M 49.08M 52.23M 61.13M
Other SG&A
320.93M 373.95M 416.17M 431.85M
SGA Growth
+21.86% +15.30% +10.72% +5.25%
Other Operating Expense
- - - -
-
Unusual Expense
38.72M 9.19M 43.75M 2.13M
EBIT after Unusual Expense
72.53M 158.01M 164.39M 220.22M
Non Operating Income/Expense
9.60M (737.00K) 3.97M 1.74M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
18.50M 15.88M 16.50M 9.89M
Interest Expense Growth
+48.87% -14.20% +3.91% -40.06%
Gross Interest Expense
18.50M 15.88M 16.50M 9.89M
Interest Capitalized
- - - -
-
Pretax Income
63.63M 141.40M 151.87M 212.07M
Pretax Income Growth
-12.73% +122.23% +7.40% +39.64%
Pretax Margin
+6.41% +12.10% +11.60% +15.58%
Income Tax
20.25M 26.00M 34.31M 44.39M
Income Tax - Current - Domestic
5.27M 11.29M 35.65M 37.93M
Income Tax - Current - Foreign
9.94M 8.94M 9.53M 12.09M
Income Tax - Deferred - Domestic
3.77M 6.62M (4.03M) (4.78M)
Income Tax - Deferred - Foreign
1.28M (843.00K) (6.84M) (842.00K)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
43.38M 115.40M 117.56M 167.68M
Minority Interest Expense
- - - -
-
Net Income
43.38M 115.40M 117.56M 167.68M
Net Income Growth
-45.42% +166.05% +1.87% +42.64%
Net Margin Growth
+4.37% +9.87% +8.98% +12.32%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
43.38M 115.40M 117.56M 167.68M
Preferred Dividends
- - - -
-
Net Income Available to Common
43.38M 115.40M 117.56M 167.68M
EPS (Basic)
0.8497 2.2724 2.3184 3.3316
EPS (Basic) Growth
-45.80% +167.44% +2.02% +43.70%
Basic Shares Outstanding
51.05M 50.78M 50.71M 50.33M
EPS (Diluted)
0.8446 2.2443 2.2872 3.3053
EPS (Diluted) Growth
-45.49% +165.72% +1.91% +44.51%
Diluted Shares Outstanding
51.35M 51.42M 51.40M 50.73M
EBITDA
209.00M 260.51M 305.35M 337.93M
EBITDA Growth
+16.88% +24.65% +17.22% +10.67%
EBITDA Margin
+21.04% +22.29% +23.33% +24.83%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 90.20
Number of Ratings 11 Current Quarters Estimate 1.25
FY Report Date 12 / 2025 Current Year's Estimate 4.914
Last Quarter’s Earnings 1.27 Median PE on CY Estimate N/A
Year Ago Earnings 4.57 Next Fiscal Year Estimate 5.483
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 11 11 11 10
Mean Estimate 1.25 1.30 4.91 5.48
High Estimates 1.28 1.34 4.95 5.62
Low Estimate 1.18 1.25 4.85 5.30
Coefficient of Variance 2.43 1.70 0.58 1.88

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 5 7 7
OVERWEIGHT 2 2 2
HOLD 4 2 1
UNDERWEIGHT 0 0 1
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Haemonetics Corp. - HAE

Date Name Shares Transaction Value
May 21, 2025 James C. D'Arecca EVP, Chief Financial Officer 21,935 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 James C. D'Arecca EVP, Chief Financial Officer 15,396 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Laurie A. Miller SVP, Human Resources 20,474 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Laurie A. Miller SVP, Human Resources 6,928 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Roy Galvin President, Global Plasma & BC 13,998 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Roy Galvin President, Global Plasma & BC 14,626 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Michelle L. Basil EVP and General Counsel 34,167 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Michelle L. Basil EVP and General Counsel 12,317 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Christopher A. Simon President & CEO; Director 335,112 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Christopher A. Simon President & CEO; Director 46,342 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Maryanne Farris VP, Chief Accounting Officer 1,816 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Maryanne Farris VP, Chief Accounting Officer 1,732 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Frank W. Chanx EVP, Chief Operating Officer 5,689 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Frank W. Chanx EVP, Chief Operating Officer 12,317 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Farris Maryanne Maunsell VP, Chief Accounting Officer 1,084 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $69.38 per share 75,207.92
May 20, 2025 Farris Maryanne Maunsell VP, Chief Accounting Officer 1,016 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $70.31 per share 71,434.96

Haemonetics Corp. in the News